Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome FoundfiledCriticalWellcome Found
Priority to AR31972991ApriorityCriticalpatent/AR245779A1/en
Application grantedgrantedCritical
Publication of AR245779A1publicationCriticalpatent/AR245779A1/en
Preparation Of Compounds By Using Micro-Organisms
(AREA)
Micro-Organisms Or Cultivation Processes Thereof
(AREA)
Peptides Or Proteins
(AREA)
Abstract
UN PROCESO PARA PREPARAR UN VECTOR, QUE COMPRENDE LA INCORPORACION DE UNA SECUENCIA DE ADN QUE CODIFICA UNA PROTEINA FUSIONANTE QUE CONTIENE EL HA DEL VIRUS DE LA GRIPE EN UN SITIO DEL CUAL, ESTANDO NORMALMENTE OCUPADO POR UN EPITOPO ANTIGENICO NATURAL DEL MISMO, SE PROPORCIONA UN EPITOPO ANTIGENICO DIFERENTE, ENTRE EL COMIENZO TRADUCCIONAL Y LAS SENALES DE DETENCION EN UN VECTOR QUE ESCAPAZ, AL SER PROPORCIONADO EN UN HUESPED EUCARIOTICO, DE EXPRESAR DICHA PROTEINA FUSIONADA Y DE PROPORCIONAR UN PROMOTOR PARA LA SECUENCIA.A PROCESS TO PREPARE A VECTOR, WHICH INCLUDES THE INCORPORATION OF A DNA SEQUENCE THAT CODES A MERGER PROTEIN CONTAINING THE HA OF THE INFLUENZA VIRUS IN A SITE OF WHICH, NORMALLY OCCUPIED BY A NATURAL ANTIGENIC EPITOPE, IS PROVIDED DIFFERENT ANTIGENIC EPITOPE, BETWEEN THE TRANSLATION BEGINNING AND THE SIGNALS OF DETENTION IN A VECTOR THAT ESCAPES, TO BE PROVIDED IN A EUCHARIOTIC GUEST, TO EXPRESS SUCH A FUSED PROTEIN AND TO PROVIDE A PROMOTER FOR THE SEQUENCE.
AR31972991A1991-05-211991-05-21A dna sequence which codifies a fused protein.
AR245779A1
(en)
AN IMMUNOGENIC, THERAPEUTIC OR PROPHYLACTIC COMPOSITION, INCLUDING AN ISOLATED POLYPEPTIDE, AN ISOLATED ANTIBODY THAT IS LINKED TO SUCH A POLYPEPTIDE AND A VACCINE THAT UNDERSTANDS IT.
BIOTECHNOLOGICAL METHOD FOR THE PRODUCTION OF ANTIGENIC PEPTIDES RELATED TO THE ANTIGEN P ASSOCIATED WITH MELANOMA, AND TO PREPARE VACCINES THAT CONTAIN THEM.